NCT07024147

JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma

An Open-Label, Single-arm Study of JWCAR239 in the Treatment of Relapse / Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Peking University Cancer Hospital & Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

JWCAR239 is a CD19/CD20 CAR-T product. This trial is intended to evaluate the safety, PK/PD and efficacy of JWCAR239 in patients with B Cell Non-Hodgkin Lymphoma (B-NHL)

Detailed description

JWCAR239 is a CD19/CD20 CAR-T product. By targeting both CD19 and CD20, it is expected to overcome some limitations with CD19 or CD20 single target products. In this study, patients with B B-NHL will be enrolled to receive JWCAR239. PK/PD properties and preliminary efficacy and safety will be evaluated. Each subject will receive JWCAR239 once and is followed up for up to 2 years.

Conditions

• B-Cell Non-Hodgkin Lymphoma
• Large B Cell Diffuse Lymphoma
• Follicular Lymphoma
• Marginal Zone B Cell Lymphoma
• Mantle Cell Lymphoma (MCL)

Interventions

Type	Name	Description
BIOLOGICAL	JWCAR239	A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells targeting CD19/CD20
DRUG	Fludarabine	Administered according to package insert
DRUG	Cyclophosphamide	Administered according to package insert

Timeline

• Start date: 2025-07-01
• Primary completion: 2027-07-01
• Completion: 2030-07-01
• First posted: 2025-06-17
• Last updated: 2025-06-17

Locations

1 site across 1 country: China